Macro vascular Outcomes To date, no clinical trials have conclusively demonstrated that saxagliptin or any other antidiabetic agent reduces the risk of major macro vascular complications, such as myocardial infarction, stroke, or cardiovascular mortality
In research, it is studied for tissue remodeling, fibroblast signaling, and copper transport mechanisms
Why Results May Differ Between People Even within a controlled clinical trial, participants do not all respond in the same way
Total and bioavailable 25-hydroxyvitamin D is not associated with improved sexual dysfunction following vitamin D supplementation in women with polycystic ovarian syndrome: a pilot study
Finally, lets consider ad augusta per angusta to glory through narrow spaces, by continuing to follow the data with GLP-1 diabetes drugs